Cortina Asset Management’s Pacira BioSciences PCRX Stock Holding History

Cortina Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$9.07M	Buy	208,471 +26,427	+15%	+$1.12M	0.56%	66
2019 Q1	$6.93M	Sell	182,044 -42,316	-19%	-$1.65M	0.43%	94
2018 Q4	$9.65M	Sell	224,360 -164,839	-42%	-$7.69M	0.59%	54
2018 Q3	$19.1M	Sell	389,199 -16,851	-4%	-$728K	0.89%	27
2018 Q2	$13M	Buy	406,050 +83,229	+26%	+$2.87M	0.61%	50
2018 Q1	$10.1M	Buy	322,821 +55,079	+21%	+$1.96M	0.49%	67
2017 Q4	$12.2M	Sell	267,742 -3,662	-1%	-$145K	0.54%	61
2017 Q3	$10.2M	Buy	271,404 +27,544	+11%	+$1.11M	0.42%	71
2017 Q2	$11.6M	Buy	243,860 +24,014	+11%	+$1.11M	0.49%	63
2017 Q1	$10M	Buy	219,846 +61,215	+39%	+$2.65M	0.42%	79
2016 Q4	$5.12M	Buy	158,631 +83,777	+112%	+$2.8M	0.21%	184
2016 Q3	$2.56M	Buy	+74,854	New	+$2.93M	0.11%	217

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Cortina Asset Management's PCRX Position: Q2 2019 in Review

Cortina Asset Management increased its Pacira BioSciences (PCRX) stake by 15% in Q2 2019, buying an estimated $1.12M and bringing the position to 208,471 shares worth $9.07M. The position accounts for 0.56% of the portfolio, ranked #66.

Cortina Asset Management first reported a position in PCRX in Q3 2016 and has held it in 12 quarters since. The position peaked at $19.1M in Q3 2018. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

Cortina Asset Management held 208,471 shares of Pacira BioSciences worth $9.07M as of Q2 2019.
Cortina Asset Management bought 26,427 Pacira BioSciences shares in Q2 2019, an estimated $1.12M.
Pacira BioSciences made up 0.56% of Cortina Asset Management's portfolio in Q2 2019, its #66 holding.
Cortina Asset Management first reported a position in Pacira BioSciences in Q3 2016 and has held it in 12 quarters since.
Cortina Asset Management's Pacira BioSciences position peaked at $19.1M in Q3 2018.
218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Cortina Asset Management's 13F filing for Q2 2019, filed 2 Jul 2019.